Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA INC. (D.N.J. 2014)

OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA INC. (D.N.J. 2014)

Docket		Date Filed	2014-05-16
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	None	Referred To	Magistrate Judge Karen M. Will
Patents	7,053,092; 8,017,615; 8,580,796; 8,642,600; 8,642,760; 8,759,350
Link to Docket	External link to docket

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. ZYDUS PHARMACEUTICALS USA INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-02-19	151		Entry of Summary Judgment Concerning U.S. Patent No. 8,759,350, Certification of Judgment Under Rule 54… 16 May 2014 1:14-cv-03168-JBS-KMW Patent None District Court, D. New Jersey	External link to document
2015-10-13	169		7,053,092 (“the ’092 patent”), 8,017,615 (“the ’615 patent”), 8,580,796 (“the ’796 patent”), 8,…’600 patent”), 8,642,760 (“the ’760 patent”), and 8,759,350 (“the ’350 patent” or the “Patent”). The…drug claimed in a patent or the use of which is claimed in a patent” prior to the patent’s expiration. …various patents covering Otsuka’s brand name aripiprazole product, Abilify®. 1 1 The patents asserted…actions specifically include: U.S. Patent Nos. 5,006,528 (“the ’528 patent”), Case 1:14-cv-03168-JBS-KMW Document	External link to document
2016-04-12	240		5,006,528 (“the ’528 patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (“the ’615 patent”), 8,580,796 (“…(“the ’796 patent”), 8,642,600 (“the ’600 patent”), and 8,642,760 (“the ’760 patent”). …asserted claims of U.S. Patent No. 8,759,350 (hereinafter, “the ’350 patent”), to mean “a single dosage… 1 The patents asserted in these related infringement actions generally include: U.S. Patent Nos. 5,…series of related patents: three directed at Otsuka’s aripiprazole polymorph patents (the ’615, the ’	External link to document